1. Ma, Jian, Li, Lei, Ma, Bohan, Wei, Wenyi, Li, Lei. 2024. MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation. In Nature communications, 15, 1871. doi:10.1038/s41467-024-45796-w. https://pubmed.ncbi.nlm.nih.gov/38424044/
2. Kreuger, Inger Z M, Slieker, Roderick C, van Groningen, Tim, van Doorn, Remco. 2022. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma. In The Journal of investigative dermatology, 143, 18-25.e1. doi:10.1016/j.jid.2022.07.016. https://pubmed.ncbi.nlm.nih.gov/36123181/
3. Sakach, Elizabeth, Keskinkilic, Merve, Wood, Sarah, Canning, Madison, Kalinsky, Kevin. 2023. CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed? In Current treatment options in oncology, 24, 1103-1119. doi:10.1007/s11864-023-01109-9. https://pubmed.ncbi.nlm.nih.gov/37314645/
4. Kanoe, H, Nakayama, T, Murakami, H, Sasaki, M S, Toguchida, J. . Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation. In Anticancer research, 18, 2317-21. doi:. https://pubmed.ncbi.nlm.nih.gov/9703873/
5. Watt, April C, Cejas, Paloma, DeCristo, Molly J, Zhao, Jean J, Goel, Shom. 2020. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. In Nature cancer, 2, 34-48. doi:10.1038/s43018-020-00135-y. https://pubmed.ncbi.nlm.nih.gov/33997789/
6. Li, Jinxiao, Shang, Luorui, Zhou, Fangyuan, Chen, Guo, Yang, Shenglan. 2023. Herba Patriniae and its component Isovitexin show anti-colorectal cancer effects by inducing apoptosis and cell-cycle arrest via p53 activation. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 168, 115690. doi:10.1016/j.biopha.2023.115690. https://pubmed.ncbi.nlm.nih.gov/37939611/
智鼠故事 
